Binding molecules to the human OX40 receptor

Details for Australian Patent Application No. 2008338591 (hide)

Owner Bristol-Myers Squibb Company Pfizer Inc.

Inventors Rajpal, Arvind; Min, Jing; Thiele, Barrett Richard; Paradis, Timothy Joseph; Wu, Yi; Toy, Kristopher; Finn, Rory Francis; Huang, Haichun; Laio, Wei; Brams, Peter; Gladue, Ronald Paul; Devaux, Brigitte; Leblanc, Heidi N.; Wu, Yanli

Agent Allens Arthur Robinson

Pub. Number AU-A-2008338591

PCT Pub. Number WO2009/079335

Priority 61/013,947 14.12.07 US

Filing date 11 December 2008

Wipo publication date 25 June 2009

International Classifications

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

10 June 2010 PCT application entered the National Phase

  PCT publication WO2009/079335 Priority application(s): WO2009/079335

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008338594-Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (HSAA)

2008338586-Self-expanding devices and methods therefor